Follicular granulosa cell proliferation

Follicular granulosa cell proliferation is a fundamental biological process within the mammalian ovary, characterized by the rapid mitotic expansion of somatic granulosa cells (GCs) that surround the developing oocyte [1][9]. This proliferation is essential for follicular maturation, the formation of the fluid-filled antrum, and the synthesis of reproductive steroids, primarily estradiol, which coordinates the female reproductive cycle [5][10]. The process is primarily driven by the binding of follicle-stimulating hormone (FSH) to its specific receptor (FSHR) on GCs, supported by local paracrine factors such as growth differentiation factor 9 (GDF9), bone morphogenetic proteins (BMPs), and insulin-like growth factors (IGFs) [7][11][12]. Dysregulation of this proliferative activity is a central component of several reproductive pathologies [2][9]. Impaired granulosa cell proliferation leads to follicular atresia and is associated with premature ovarian insufficiency (POI) and infertility [10][13]. Conversely, excessive or uncontrolled proliferation is a hallmark of polycystic ovary syndrome (PCOS) and can contribute to the development of granulosa cell tumors [4][9]. Therapeutic management of this process involves the use of gonadotropins to stimulate follicle growth in fertility treatments or GnRH modulators to regulate the hormonal axis in conditions like endometriosis and hormone-sensitive cancers [8][10].

Other names

Granulosa cell proliferationOvarian granulosa cell proliferationFollicular GC proliferationGranulosa cell growth

The process is modulated through the pharmacological activation of gonadotropin receptors (FSHR and LHCGR) or by altering endogenous hormone levels via the hypothalamic-pituitary-ovarian (HPO) axis [9][10]. Drugs like follitropin act as direct agonists at the FSH receptor on granulosa cells to stimulate cAMP/PKA and PI3K/Akt signaling pathways, which drive the cell cycle [11][12]. Aromatase inhibitors and selective estrogen receptor modulators (SERMs) increase endogenous FSH production to promote follicle maturation, while GnRH analogs are used to suppress or synchronize this proliferative activity [8][10].